Status:
UNKNOWN
Cytomegalovirus (CMV) Reactivation in Allogeneic HSCT Recipient
Lead Sponsor:
Melbourne Health
Collaborating Sponsors:
Peter MacCallum Cancer Centre, Australia
Western Sydney Local Health District
Conditions:
Cytomegalovirus Infections
Haematological Malignancy
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This study consists of two parts: 1) Part 1, a retrospective part on 250 consecutive patients following allogeneic haematopoietic stem cell transplant (allo-HSCT) at the Royal Melbourne Hospital from ...
Detailed Description
Cytomegalovirus (CMV) infection is recognised as one of the most common and important infectious complication of allogeneic haematopoietic stem cell transplantation (allo-HSCT). Despite the serious cl...
Eligibility Criteria
Inclusion
- For the retrospective cohort, all 250 consecutive allo-HSCT patients between 2012 to 2017 at the Royal Melbourne Hospital will be included, with CMV-negative patients acting as controls for economic comparisons.
- For the prospective cohort, patients undergoing allo-HSCT, at risk of CMV disease (D+/R+, D-/R+ D+/R-), and able to provide informed consent.
Exclusion
- For the retrospective cohort, no exclusion is set.
- For the prospective cohort, patients who has CMV disease at the time of enrolment and patients who are unable to provide informed consent.
Key Trial Info
Start Date :
April 17 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
370 Patients enrolled
Trial Details
Trial ID
NCT03806764
Start Date
April 17 2018
End Date
December 31 2023
Last Update
June 1 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal Melbourne Hospital
Parkville, Victoria, Australia, 3050